Please ensure Javascript is enabled for purposes of website accessibility

Do Fish Oil Drugmakers Need to Worry About Generics?

By Max Macaluso and Dave Williamson - Sep 18, 2013 at 6:48PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A recent court ruling might mean generic Lovaza will hit the market in the near future.

A recent court decision has ostensibly made if possible for generic-drug companies to manufacture their own versions of the fish oil pill Lovaza. How does this news affect shareholders of GlaxoSmtihKline (GSK -0.50%), the company that sells the drug in the U.S., and how can this decision affect rivals like struggling biotech company Amarin (AMRN 12.40%)

Analysts David Williamson and Max Macaluso discuss these topics in the following video segment from The Motley Fool's health-care show Market Checkup.

David Williamson owns shares of Amarin. Max Macaluso, Ph.D., has no position in any stocks mentioned. The Motley Fool recommends GlaxoSmithKline. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Amarin Corporation plc Stock Quote
Amarin Corporation plc
AMRN
$1.45 (12.40%) $0.16
GSK Stock Quote
GSK
GSK
$40.37 (-0.50%) $0.20
AstraZeneca PLC Stock Quote
AstraZeneca PLC
AZN
$65.23 (-1.20%) $0.80
AbbVie Inc. Stock Quote
AbbVie Inc.
ABBV
$139.90 (1.35%) $1.86

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
377%
 
S&P 500 Returns
123%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/08/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.